Delayed
Nasdaq
12:43:07 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
3.48
USD
|
+7.08%
|
|
+8.07%
|
-32.30%
|
Fiscal Period: März |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Capitalization
1 |
21.65
|
305.3
|
256.1
|
27.35
|
142.7
|
87.83
|
-
|
-
|
Enterprise Value (EV)
1 |
21.65
|
305.3
|
256.1
|
27.35
|
142.7
|
27.23
|
87.83
|
87.83
|
P/E ratio
|
-0.88
x
|
-4.35
x
|
-4.96
x
|
-0.44
x
|
-3.47
x
|
-1.49
x
|
-1.72
x
|
-1.76
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
280
x
|
231
x
|
-120
x
|
134
x
|
444
x
|
333
x
|
35.1
x
|
EV / Revenue
|
-
|
280
x
|
231
x
|
-120
x
|
134
x
|
138
x
|
333
x
|
35.1
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-0.51
x
|
-1.29
x
|
-0.84
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-195%
|
-77.4%
|
-118%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,640
|
4,778
|
6,884
|
7,311
|
27,025
|
27,025
|
-
|
-
|
Reference price
2 |
13.20
|
63.90
|
37.20
|
3.741
|
5.280
|
3.250
|
3.250
|
3.250
|
Announcement Date
|
29/06/20
|
29/06/21
|
23/06/22
|
28/06/23
|
11/06/24
|
-
|
-
|
-
|
Fiscal Period: März |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net sales
1 |
-
|
1.09
|
1.109
|
-0.2273
|
1.064
|
0.1978
|
0.2637
|
2.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.8
|
-17.93
|
-47.78
|
-59.27
|
-33.02
|
-70.43
|
-83.8
|
-79.38
|
Operating Margin
|
-
|
-1,646.06%
|
-4,308.68%
|
26,074.79%
|
-3,103.48%
|
-35,614.41%
|
-31,784.05%
|
-3,175.22%
|
Earnings before Tax (EBT)
1 |
-20.77
|
-17.93
|
-47.76
|
-59.24
|
-29.36
|
-66.96
|
-82.07
|
-78.48
|
Net income
1 |
-22.04
|
-42.32
|
-48.71
|
-59.25
|
-29.36
|
-66.96
|
-82.07
|
-78.48
|
Net margin
|
-
|
-3,884.33%
|
-4,392.42%
|
26,065.86%
|
-2,759.59%
|
-33,862.96%
|
-31,126.53%
|
-3,139.22%
|
EPS
2 |
-15.00
|
-14.70
|
-7.500
|
-8.510
|
-1.520
|
-2.180
|
-1.887
|
-1.845
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-53
|
-68
|
-104
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-26,801.52%
|
-25,789.81%
|
-4,160%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/06/20
|
29/06/21
|
23/06/22
|
28/06/23
|
11/06/24
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
0.3579
|
0.0389
|
0.3101
|
-0.8925
|
0.1796
|
0.1756
|
0.1776
|
0.2777
|
0.4114
|
0.1973
|
0.2985
|
0.099
|
0.099
|
0.099
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.54
|
-16.69
|
-19.77
|
-17.49
|
-9.766
|
-12.24
|
-6.998
|
-6.78
|
-7.884
|
-11.4
|
-13.3
|
-16.84
|
-19.41
|
-20.88
|
Operating Margin
|
-2,945.01%
|
-42,912.6%
|
-6,376.36%
|
1,959.59%
|
-5,437.92%
|
-6,969.87%
|
-3,940.2%
|
-2,441.56%
|
-1,916.38%
|
-5,777.5%
|
-4,454.94%
|
-17,010.1%
|
-19,604.04%
|
-21,092.42%
|
Earnings before Tax (EBT)
1 |
-10.54
|
-16.69
|
-19.77
|
-17.48
|
-9.761
|
-12.23
|
-6.901
|
-6.588
|
-6.35
|
-9.7
|
-12.36
|
-15.92
|
-18.55
|
-20.13
|
Net income
1 |
-10.74
|
-16.69
|
-19.78
|
-17.48
|
-9.761
|
-12.23
|
-6.903
|
-6.588
|
-6.35
|
-9.791
|
-12.36
|
-15.92
|
-18.55
|
-20.13
|
Net margin
|
-3,001.73%
|
-42,900.77%
|
-6,377.39%
|
1,958.9%
|
-5,434.97%
|
-6,962.98%
|
-3,886.88%
|
-2,372.24%
|
-1,543.46%
|
-4,962.7%
|
-4,141.04%
|
-16,082.32%
|
-18,738.89%
|
-20,333.84%
|
EPS
2 |
-1.500
|
-2.700
|
-3.000
|
-2.400
|
-1.500
|
-0.8433
|
-0.9400
|
-0.6600
|
-0.2200
|
-0.2500
|
-0.4050
|
-0.5200
|
-0.6000
|
-0.6550
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/02/22
|
23/06/22
|
11/08/22
|
10/11/22
|
07/02/23
|
28/06/23
|
10/08/23
|
09/11/23
|
13/02/24
|
11/06/24
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
60.6
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-53
|
-68
|
-104
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.28
|
-
|
-
|
-
|
0.5
|
-
|
-
|
Capex / Sales
|
-
|
25.28%
|
-
|
-
|
-
|
252.84%
|
-
|
-
|
Announcement Date
|
29/06/20
|
29/06/21
|
23/06/22
|
28/06/23
|
11/06/24
|
-
|
-
|
-
|
Last Close Price
3.25
USD Average target price
14
USD Spread / Average Target +330.77% Consensus |
1st Jan change
|
Capi.
|
---|
| -32.30% | 87.83M | | +16.41% | 122B | | +19.30% | 115B | | +21.22% | 26.64B | | -23.74% | 19.91B | | -17.47% | 16.32B | | -45.95% | 15.52B | | -18.39% | 15.49B | | +64.16% | 14.83B | | +2.31% | 13.67B |
Bio Therapeutic Drugs
|